Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 8:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 569 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: blood sample (DNA) Clear all
Active, not recruiting Phase 2 Interventional

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

NCT03375307
View directory record Official record
Conditions
Advanced Bladder Carcinoma, Advanced Genitourinary System Carcinoma, Metastatic Bladder Carcinoma, Metastatic Genitourinary System Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Positron Emission Tomography
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
17
States / cities
Encinitas, California • Irvine, California • La Jolla, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 10, 2026, 8:57 AM EDT
Recruiting Not applicable Interventional

Circulating Tumor DNA in Stage I, II, and III Germ-Cell Tumors

NCT07401316
View directory record Official record
Conditions
Germ Cell Cancer Metastatic
Interventions
Whole blood for ctDNA
Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 10, 2026, 8:57 AM EDT
Completed Not applicable Interventional

Piloting At-birth Point of Care HIV Testing Strategies in Kenya

NCT03435887
View directory record Official record
Conditions
HIV Infections
Interventions
Alere q HIV-1/2 Detect for point of care infant testing, GeneXpert HIV-1 Qual for point of care infant testing, HIV DNA PCR testing (Standard of Care)
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1,999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Sep 10, 2026, 8:57 AM EDT
Recruiting Not applicable Interventional

TCF-001 TRACK (Target Rare Cancer Knowledge) Study

NCT04504604
View directory record Official record
Conditions
Rare Cancers, Cholangiocarcinoma, Cancer of Unknown Primary Site
Interventions
FoundationOne CDx and FoundationOne Liquid CDx
Diagnostic Test
Lead sponsor
TargetCancer Foundation
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 10, 2026, 8:57 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers Results available

A Study to Evaluate AAV9 Neutralizing Antibody Seroconversion in Household Contacts.

NCT04543357
View directory record Official record
Conditions
Household Contacts
Interventions
Blood Draw
Other
Lead sponsor
Pfizer
Industry
Eligibility
0 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Sep 10, 2026, 8:57 AM EDT
Recruiting No phase listed Observational

EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

NCT06401421
View directory record Official record
Conditions
Breast Cancer
Interventions
ctDNA MRD test
Diagnostic Test
Lead sponsor
Exact Sciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
53
States / cities
Anchorage, Alaska • Palo Alto, California • Torrance, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Sep 10, 2026, 8:57 AM EDT
Completed Phase 2 Interventional Results available

Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation

NCT01267812
View directory record Official record
Conditions
Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Stage I Mantle Cell Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Mantle Cell Lymphoma
Interventions
bortezomib, rituximab, laboratory biomarker analysis, immunohistochemistry staining method, RNA analysis, gene expression analysis, DNA analysis, pharmacological study, pharmacogenomic studies, Questionnaire Administration
Drug · Biological · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
19 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
2
States / cities
Duarte, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 10, 2026, 8:57 AM EDT
Active, not recruiting No phase listed Observational

Detection of Plasma DNA Methylation in Peripheral Blood From Patients With Resectable Liver Cancer

NCT04856046
View directory record Official record
Conditions
Resectable Hepatocellular Carcinoma
Interventions
Biospecimen Collection, Electronic Health Record Review
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 10, 2026, 8:57 AM EDT
Recruiting Not applicable Interventional

Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.

NCT06394869
View directory record Official record
Conditions
Hematuria - Cause Not Known
Interventions
Cxbladder Triage Plus
Diagnostic Test
Lead sponsor
Pacific Edge Limited
Industry
Eligibility
18 Years to 88 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
20
States / cities
Homewood, Alabama • Mobile, Alabama • Fresno, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 10, 2026, 8:57 AM EDT
Completed Phase 4 Interventional Results available

Study EvAluating Genotypes While Using Lucentis 2

NCT01464723
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Ranibizumab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
50 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Sep 10, 2026, 8:57 AM EDT
Completed No phase listed Observational

Transforming Research and Clinical Knowledge in Traumatic Brain Injury

NCT02119182
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
In-Person Outcome Assessment, Phone Outcome Assessment, 3T Magnetic Resonance Imaging (MRI), Blood Draw for Plasma, DNA, Serum, RNA
Behavioral · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
1 Year to 100 Years
Enrollment
2,996 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
23
States / cities
San Francisco, California • Denver, Colorado • Englewood, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Sep 10, 2026, 8:57 AM EDT
Completed No phase listed Observational

Epidemiological Study to Monitor Study Participants With Resected Stage II (High Risk) or Stage III Colorectal Cancer for Circulating Tumor DNA Before, During and After Their Treatment With Adjuvant Chemotherapy

NCT04813627
View directory record Official record
Conditions
Colorectal Cancer Stage II, Colorectal Cancer Stage III
Interventions
Regular blood sample collection for ctDNA assessment
Procedure
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
2,079 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
17
States / cities
California City, California • Concord, California • Greenbrae, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 10, 2026, 8:57 AM EDT
Completed No phase listed Observational

Developing Mouse Models of Breast Cancer Using Tissue Samples From Women With Breast Cancer

NCT00897468
View directory record Official record
Conditions
Breast Cancer
Interventions
laboratory biomarker analysis, medical chart review
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 3, 2018 · Synced Sep 10, 2026, 8:57 AM EDT
Terminated Phase 1 Interventional

Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal Cancer

NCT01126450
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer
Interventions
lenalidomide, cetuximab, mutation analysis, polymerase chain reaction, polymorphism analysis
Drug · Biological · Other + 1 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Sep 10, 2026, 8:57 AM EDT
Recruiting Phase 1 Interventional

Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes

NCT05687110
View directory record Official record
Conditions
Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing, Novobiocin Sodium
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
22
States / cities
Duarte, California • Irvine, California • La Jolla, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 10, 2026, 8:57 AM EDT
Recruiting Phase 2 Interventional

Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma

NCT07096362
View directory record Official record
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
Interventions
5-Fluorouracil, Oxaliplatin, Leucovorin, Irinotecan, Gemcitabine, Nab Paclitaxel, Circulating Tumor Deoxyribonucleic acid (ctDNA) Assay
Drug · Diagnostic Test
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Sep 10, 2026, 8:57 AM EDT
Completed Phase 1 Interventional

Differences in Evoked Intracellular Interferon Signaling Pathways Using Single Cell Phosphoprotein Profiling

NCT01217359
View directory record Official record
Conditions
Hepatitis C
Interventions
Interferon Alfa-2b
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 14, 2016 · Synced Sep 10, 2026, 8:57 AM EDT
Terminated Not applicable Interventional Results available

Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

NCT01280643
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
fluorouracil, leucovorin calcium, oxaliplatin, irinotecan hydrochloride, bevacizumab, cetuximab, capecitabine, mutation analysis, gene expression analysis, laboratory biomarker analysis, immunohistochemistry staining method, nucleic acid sequencing, protein expression analysis, polymerase chain reaction, DNA analysis
Drug · Biological · Genetic + 1 more
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 14, 2021 · Synced Sep 10, 2026, 8:57 AM EDT
Completed Phase 2 Interventional Results available

Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck

NCT00720304
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
docetaxel, erlotinib hydrochloride, fluorescence in situ hybridization, polymerase chain reaction, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, therapeutic conventional surgery, intensity-modulated radiation therapy, radiation therapy
Drug · Genetic · Other + 2 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Sep 10, 2026, 8:57 AM EDT
Completed No phase listed Observational

Platelets in Pregnancy

NCT06194643
View directory record Official record
Conditions
Hypertensive Disorder of Pregnancy
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
66 participants
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 10, 2026, 8:57 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

APOL1 Genetic Testing in African Americans

NCT05656261
View directory record Official record
Conditions
Genetic Predisposition, Chronic Kidney Diseases, Nephropathy, APOL1 Associated Kidney Disease, Disparities
Interventions
Assessment of the frequency of APOL-1 renal risk variant in the black population, and evaluating their attitudes about genetic testing and APOL1 genotype via self-administered surveys
Genetic
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 90 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Sep 10, 2026, 8:57 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Blood Collection Sub-Study for CRC Screening in Individuals 45-49 at Average Risk for CRC.

NCT03741166
View directory record Official record
Conditions
Colo-rectal Cancer
Interventions
Blood Sample Collection
Other
Lead sponsor
Exact Sciences Corporation
Industry
Eligibility
45 Years to 49 Years
Enrollment
871 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
37
States / cities
Phoenix, Arizona • Camarillo, California • Laguna Hills, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 16, 2021 · Synced Sep 10, 2026, 8:57 AM EDT
Recruiting Not applicable Interventional

Minimal Residual Disease Testing for the Early Detection of Cancer Recurrence in Resectable Stage II-IV Colorectal Cancer Patients

NCT07125729
View directory record Official record
Conditions
Resectable Colorectal Carcinoma, Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8
Interventions
Biospecimen Collection, cfDNA or ctDNA Measurement, Electronic Health Record Review
Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Goodyear, Arizona • Corona, California • Duarte, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 10, 2026, 8:57 AM EDT
Completed No phase listed Observational

Clinical Evaluation of the SEQureDx Trisomy Test in Low Risk Pregnancies

NCT01597063
View directory record Official record
Conditions
Aneuploidy, Down Syndrome, Noninvasive Prenatal Screening
Interventions
SEQureDx Trisomy Test
Device
Lead sponsor
Sequenom, Inc.
Industry
Eligibility
18 Years to 34 Years · Female only
Enrollment
3,333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
27
States / cities
Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2016 · Synced Sep 10, 2026, 8:57 AM EDT